Dataset from Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

The purpose of this study is to assess the immunogenicity and safety of the Infanrix hexa
booster dose given at 11-18 months of age to infants who received primary vaccination at 6-14
weeks. All infants in this booster study were born to pregnant women who participated in the
study 116945 [DTPA (BOOSTRIX)-047] and having received the full primary vaccination series as
per protocol requirement in study 201330 [DTPA (BOOSTRIX)-048.